Format

Send to

Choose Destination
See comment in PubMed Commons below
Eur J Nucl Med Mol Imaging. 2011 May;38 Suppl 1:S41-7. doi: 10.1007/s00259-011-1769-1. Epub 2011 Apr 12.

Three-dimensional radiobiological dosimetry (3D-RD) with 124I PET for 131I therapy of thyroid cancer.

Author information

1
The Russell H. Morgan Department of Radiology, Division of Nuclear Medicine, Johns Hopkins University, School of Medicine, Baltimore, MD, USA. gsgouros@jhmi.edu

Abstract

Radioiodine therapy of thyroid cancer was the first and remains among the most successful radiopharmaceutical (RPT) treatments of cancer although its clinical use is based on imprecise dosimetry. The positron emitting radioiodine, (124)I, in combination with positron emission tomography (PET)/CT has made it possible to measure the spatial distribution of radioiodine in tumors and normal organs at high resolution and sensitivity. The CT component of PET/CT has made it simpler to match the activity distribution to the corresponding anatomy. These developments have facilitated patient-specific dosimetry (PSD), utilizing software packages such as three-dimensional radiobiological dosimetry (3D-RD), which can account for individual patient differences in pharmacokinetics and anatomy. We highlight specific examples of such calculations and discuss the potential impact of (124)I PET/CT on thyroid cancer therapy.

PMID:
21484384
PMCID:
PMC3172686
DOI:
10.1007/s00259-011-1769-1
[Indexed for MEDLINE]
Free PMC Article
PubMed Commons home

PubMed Commons

0 comments
How to join PubMed Commons

    Supplemental Content

    Full text links

    Icon for Springer Icon for PubMed Central
    Loading ...
    Support Center